Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Wacker Chemie Ag

Home Clinical Trial Sponsors and OrganizationsWacker Chemie Ag

Wacker Chemie Ag

ACTIVE

Norwaywww.wacker.comPublic16,378 employeesEstablished: 1914-01-01

Also known as:

wacker ceramics

wacker chemicals australia pty ltd

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

5

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1914

Overview

Trial Phase Distribution

Phase

Trials

Share

Not Applicable

4

80.0%

Trial Status Distribution

Completed

5

100.0%

Clinical Trials

Trials sponsored by this organization (5)

Investigation of Curcumin on symptoms of knee osteoarthritis: a two months, double blind, Placebo-controlled, randomized pilot study

Aug 202048 participants

Bioavailability of three different Resveratrol products in healthy subjects – a randomized, double-blind three-way cross-over study

May 202015 participants

Clinical study to investigate lipid modifying effects of hydroxytyrosol – a randomized, double-blind, placebo-controlled parallel study

Aug 201892 participants

Effects of hydroxytyrosol on protection of LDL particles from oxidative damage: a randomized, double-blind, placebo-controlled cross-over study

Jul 201630 participants

Investigation of anti-inflammatory and anti-oxidative properties of curcumin in overweight subjects: a randomized, double-blind, placebo-controlled study

Jul 201661 participants

Approvals

No approval data available

News

Wacker Biotech and Expression Manufacturing Form Strategic Partnership to Accelerate Lentiviral Gene Therapy Development

- Wacker Biotech and Expression Manufacturing have announced a strategic collaboration to advance lentiviral-based gene and cell therapy development and manufacturing. - The partnership combines Wacker's PLASMITEC® plasmid DNA platform with Expression's LentET™ viral vector technology to provide end-to-end manufacturing solutions. - The collaboration aims to streamline supply chains, reduce time to market, and enhance safety standards for viral vector biopharmaceuticals. - Expression's LentET™ platform features ultra-low homology backbones to reduce recombination risks and optimized coding sequences for enhanced potency.

On this page

Overview
Clinical Trials5
Approvals
News1

Back to Organizations